AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

Eli Lilly has acquired Engage Bio and its preclinical, non-viral DNA delivery platform. Credit: Tada Images / Shutterstock.com. Pharmaceutical giant Eli Lilly has agreed to acquire Engage Biologics ...

Cases of syphilis and gonorrhoea have tripled and quadrupled, respectively, since 2015, highlighting the need for effective treatments.

Concept Life Sciences has signed a strategic partnership with OpenBench to deliver success-based drug discovery services targeted at early-stage biotech companies.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

BMS and Hengrui will trade the greater Chinese and US rights to certain programmes, while joining forces to progress five innovative assets.